4.8 Article

Bioelectronic cell-based device provides a strategy for the treatment of the experimental model of multiple sclerosis

期刊

JOURNAL OF CONTROLLED RELEASE
卷 352, 期 -, 页码 994-1008

出版社

ELSEVIER
DOI: 10.1016/j.jconrel.2022.11.008

关键词

Cell-based device; Optogenetic; Bioelectronic; Drug delivery; Multiple sclerosis; Interferon

资金

  1. European Union [720694]

向作者/读者索取更多资源

This study presents a wireless powered optogenetic cell-based implant for subcutaneously delivering therapeutic proteins. Utilizing immortalized immune human stem cells for controlled interferon-13 release, a bioelectronic cell-based implant was established. Integration of wireless optoelectronic devices and industrial flexible high-performance equipment was demonstrated.
Wireless powered optogenetic cell-based implant provides a strategy to deliver subcutaneously therapeutic proteins. Immortalize Human Mesenchymal Stem Cells (hMSC-TERT) expressing the bacteriophytochrome diguanylate cyclase (DGCL) were validated for optogenetic controlled interferon-I3 delivery (Optoferon cells) in a bioelectronic cell-based implant. Optoferon cells transcriptomic profiling was used to elaborate an in-silico model of the recombinant interferon-I3 production. Wireless optoelectronic device integration was developed using additive manufacturing and injection molding. Implant cell-based optoelectronic interface manufacturing was established to integrate industrial flexible compact low-resistance screen-printed Near Field Communication (NFC) coil antenna. Optogenetic cell-based implant biocompatibility, and device performances were evaluated in the Experimental Autoimmune Encephalomyelitis (EAE) mouse model of multiple sclerosis.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据